Taysha Gene Therapies (TSHA) to Release Quarterly Earnings on Tuesday

Taysha Gene Therapies (NASDAQ:TSHA) will likely be issuing its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $1.5070 million for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 8:30 AM ET.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The company had revenue of $1.99 million during the quarter, compared to analysts’ expectations of $1.61 million. Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Taysha Gene Therapies Trading Down 9.8%

TSHA opened at $4.47 on Monday. The firm has a market cap of $1.22 billion, a P/E ratio of -12.99 and a beta of 1.00. Taysha Gene Therapies has a 12 month low of $1.05 and a 12 month high of $5.51. The company has a current ratio of 12.48, a quick ratio of 12.48 and a debt-to-equity ratio of 0.17. The stock has a 50-day moving average of $3.87 and a 200 day moving average of $2.99.

Wall Street Analyst Weigh In

TSHA has been the subject of several recent research reports. Robert W. Baird lifted their price target on Taysha Gene Therapies from $7.00 to $12.00 and gave the stock an “outperform” rating in a research report on Thursday, October 2nd. Bank of America started coverage on shares of Taysha Gene Therapies in a research note on Friday, July 11th. They set a “buy” rating and a $8.00 price target for the company. Chardan Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research note on Friday, October 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Taysha Gene Therapies in a research note on Thursday. Finally, Raymond James Financial assumed coverage on shares of Taysha Gene Therapies in a research note on Tuesday, October 21st. They set a “strong-buy” rating and a $13.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.67.

Insider Buying and Selling at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $3.23, for a total transaction of $646,000.00. Following the completion of the sale, the insider owned 1,006,439 shares of the company’s stock, valued at $3,250,797.97. This represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 3.78% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Marex Group plc purchased a new stake in Taysha Gene Therapies during the second quarter valued at approximately $29,000. Tower Research Capital LLC TRC increased its stake in shares of Taysha Gene Therapies by 156.5% in the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after acquiring an additional 10,742 shares during the period. E Fund Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies in the second quarter worth $31,000. Rafferty Asset Management LLC acquired a new stake in shares of Taysha Gene Therapies in the second quarter worth $274,000. Finally, Octagon Capital Advisors LP increased its stake in shares of Taysha Gene Therapies by 17.7% in the second quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock worth $29,089,000 after acquiring an additional 1,892,500 shares during the period. Hedge funds and other institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.